Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

For the last 40 years oestrogens have been prescribed for treating the menopause and their effects are beginning to be well recognised. Many epidemiological surveys have shown that giving oestrogens by themselves increases the risk of cancer of the endometrium. This most undesirable secondary effect can be neutralised if progestogens are given at the same time. It is even possible to treat endometrial hyperplasia, the precursor stage of cancer of the endometrium. No effects on cancers of the ovary, of the cervix, of the vagina and of the vulva have been found resulting from the use of replacement oestrogens. The epidemiological surveys to study the risk of cancer of the breast linked with oestrogen treatment have not shown that there is any increased risk. There are, however, still some doubts about sub-groups and in particular those women whose ovaries have been removed. As with cancer of the endometrium, taking progestogens at the same time lessens the risk, doubtless because the deficiency in progesterone is more important as a causative agent for the development of tumours in the breast than excess oestrogens. It is necessary to weigh the risks and the benefits of hormone replacement therapy after the menopause, but overall the results of studies that have been carried out until now favour greatly the prescription of such therapy.
 ...
PMID:[Cancer risk of hormone replacement treatment in the menopause]. 265 35

A human monoclonal antibody termed HMST-1 was produced by fusing lymphocytes from segments of human pelvic lymph nodes from an endometrial cancer patient with murine myeloma cells. The epitope recognized by HMST-1 was determined to be lacto-series type 1 chain-containing glycosphingolipid (Gal beta 1-3GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer) by isolating the antigen from endometrial cancer cell line SNG-II and analyzing with fast atom bombardment mass spectrometry, permethylation analysis, and exoglycosidase treatment. By the immunohistochemical avidin-biotin-peroxidase complex method, no normal endometrium and benign endometrial hyperplasia were stained with HMST-1, but HMST-1 reacted with about 35% of endometrial cancer cases. These facts indicate that the rate of expression of the antigen increases along with the course of malignancy in the endometrium. By sialidase treatment of the section, the positive rate increased to 57% in endometrial cancers and to 13% in normal endometrium, indicating that the antigen was masked with sialic acid and exposed by neuraminidase treatment. Immunohistochemistry also revealed that the antibody reacted with human fetal alimentary tract epithelium and mesothelium, indicating the oncodevelopmental nature of Gal beta 1-3GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer.
 ...
PMID:Human monoclonal antibody (HMST-1) against lacto-series type 1 chain and expression of the chain in uterine endometrial cancers. 268 63

We examined the usefulness of ultrasonography (USG) for endometrial cancer screening in postmenopausal women. 207 postmenopausal women were ultrasonographically examined. The endometrial echo was classified into 4 types: 1, anechoic; 2, hair-line; 3, linear; and 4, navicular, and was compared with histological findings. No abnormal histological findings were observed in the cases showing type 1 and 2. On the other hand, abnormal histological findings including endometrial hyperplasia, atypical hyperplasia, and endometrial cancer, were seen in 57.7% (15/26) of type 3 cases, and 65.6% (21/32) of type 4 cases. Furthermore, type 3 and 4 women had enlargement of the uterus, and an increased incidence of postmenopausal bleeding. Positive rates in the progesterone challenge test (PCT) and karyopicnotic index (KPI) were higher in type 3 and 4 cases than in type 1 and 2. It was concluded that USG is able to accurately determine the endometrial condition and is useful for identifying high-risk patients in endometrial cancer screening.
 ...
PMID:[Ultrasonographic evaluation of the endometrium in postmenopausal women to select the high risk group of endometrial carcinoma of the uterus]. 268 38

Cytodiagnosis of the precancerous lesions of the endometrium has remained unclear compared to that for cervical lesions. Endometrial cytology and biopsy have been performed for patients with atypical genital bleeding, who were over fifty, postmenopausal or nulliparous, We studied cytologic findings in cystic glandular, adenomatous and atypical hyperplasia, and compared to them in early cancer. Differential diagnosis was somewhat difficult between cystic glandular hyperplasia and benign lesions. Cytological diagnosis becomes gradually easier with progress of the lesions. A few cases with endometrial hyperplasia developed endometrial carcinoma for several years. Endometrial carcinoma has been detected even in the patients with suspicious endometrial cytology, so endometrial biopsy is still an important method. However, endometrial cytology is very easy, so we need to clarify the cytological cytological characteristics in precancerous lesions of the endometrium.
 ...
PMID:[Diagnosis of precancerous lesions of the endometrium]. 273 55

Endometrial hyperplasia has been considered as a hormone dependent lesion. Besides atypical genital bleeding, the possibility of endometrial carcinoma is also of significance. In this study, we administered 400mg daily of Danazol in 29 cases or 20mg daily of tamoxifen in 20 cases, respectively, for climacteric or postmenopausal women with different types of endometrial hyperplasia, and discussed their effect. Genital bleeding due to hyperplasia disappeared within 10-28 days in the danazol group and within 7-30 days in the tamoxifen group. In the latter group also, 2 climacteric women experienced menopause. The tortuous gland of hyperplasia became smaller and rounder. At the end of the treatment the glandular epithelium was low and showed a very poor secretory phase. The nuclei mitosis both in the glandular and stromal cells disappeared. The regression of hyperplasia was obtained after 1, 3, 6 months of danazol therapy in 37.9%, 72.4%, 93.1% and with tamoxifen therapy in 65%, 80%, 90% respectively, without undesirable side effects. In conclusion, the control of the endometrial hyperplasia with danazol and tamoxifen was suggested, and the results of the use of the suggested method were no further occurrence and/or progression of the disease. Both of the drugs were effective and safe alternative therapy for endometrial hyperplasia to progesterone.
 ...
PMID:[The effect of danazol and tamoxifen on endometrial hyperplasia]. 273 56

Serum levels of carcinoembryonic antigen (CEA), CA 125 and CA 15-3 were measured in 47 patients with endometrial cancer and 20 with endometrial hyperplasia. Before treatment elevated serum levels of CEA, CA 125 and CA 15-3 were found in 14, 43 and 32% of cancer patients, respectively. In the 20 patients with endometrial hyperplasia, CEA and CA 15-3 values were normal, while elevated CA-125 titers were detected in 1 case. There was an increasing incidence of abnormal levels of all markers in relation to a higher tumor stage (stage I: 36%; II: 66%; III: 100%). The percentage of positive marker values increased in case of deep myometrial infiltration (greater than M1) and/or poorer tumor differentiation (greater than G1). However, only percent increase in CA 15-3 positivity was significantly higher in more infiltrating (greater than M1, 7 vs. 65%, p less than 0.01) and less differentiated (greater than G1, 0 vs. 47%, p = 0.01) tumors. These findings suggest that CA 15-3 is in some way associated with the prognostic factors of the disease. All patients except 2 with no evidence of disease after surgery had normal serum marker values. Moreover, CA 125 and CA 15-3 levels reflected the clinical course of the disease during chemotherapy and seemed to be useful for monitoring response to treatment.
 ...
PMID:Multiple serum markers in patients with endometrial cancer. 274 25

Since 1971, cytological evaluation of cervical smears and endometrial aspirates was carried out in 604 women wearing CuT200 intrauterine contraceptive devices (IUDs) for periods ranging from 6 mo to 15 yr. No cases of cervical neoplasia or endometrial carcinoma were encountered, even after continuous use of the device for 15 years. Dysplastic cervical smears were, however, found in 45 postinsertional smears, and endometrial hyperplasia was detected in seven aspirates; in no cases was the dysplasia or hyperplasia higher than of moderate degree. Thirty-nine of the 45 women with postinsertional dysplastic smears were followed for 3-4 yr; in no case did the lesion progress to a higher grade or to frank malignancy. However, persistence and recurrence of dysplasia were seen in 10 women, necessitating removal of the IUDs. The incidence of cervical dysplasia and endometrial hyperplasia was found to be much higher when the IUDs had been changed than when the original devices were worn continuously. The rate of removal of IUDs because of persistent or recurring dysplasia was also much higher in the former group. Since no pregnancies were reported in any of the women wearing the original device for as long as 15 yr, we do not advocate the practice of changing the device at the end of 3 yr for maintaining contraceptive efficacy as recommended by the manufacturers; instead, we recommend the uninterrupted retention of the original device for periods not longer than 5 yr in view of occurrence of endometrial hyperplasia in two 6-yr wearers.
 ...
PMID:Cytopathological changes in human cervix and endometrium following prolonged retention of copper-bearing intrauterine contraceptive devices. 279 30

Many gynecologists use routine endometrial sampling prior to hysterectomy to detect an unsuspected endometrial carcinoma. Gynecologists who formerly performed uterine curettage under anesthesia before hysterectomy now often use an outpatient endometrial sampling technique. Although safe, this procedure is complicated by discomfort, cost, and the risk of infection or uterine perforation. The purpose of this study was to determine the utility of pre-hysterectomy endometrial sampling. Between 1981-1985, 619 patients undergoing hysterectomy had preoperative endometrial sampling using Vabra aspiration, the Novak curette, or D&C. The endometrial sampling histology was compared with that in the hysterectomy specimen. There were 30 instances in which the endometrial sampling failed to identify either endometrial hyperplasia or carcinoma. In the two cases of endometrial carcinoma, D&C was the sampling method used. The findings of this study indicate that these three techniques of endometrial sampling are equal in their diagnostic capabilities. The results confirm the need for biopsy in patients with postmenopausal bleeding or with abnormal uterine bleeding at age 35 years or older. Our findings do not support routine endometrial sampling prior to hysterectomy.
 ...
PMID:Endometrial sampling prior to hysterectomy. 291 64

The Authors studied the concentration of cytosolic and nuclear receptor for Estradiol and Progesterone in endometrial hyperplasia and carcinoma, compared with a control group. Comparative study of hormone receptor concentrations in different populations shows: 1) A significant increase in Estradiol receptors in endometrial hyperplasia (p less than 0.01); 2) A decreasing concentration of estradiol receptors with the decreasing of cellular differentiation in endometrial carcinoma (p less than 0.01); 3) A similar tendency and significance for Progesterone receptors; 4) For both receptors the tendency in the nuclear compartment is similar to that in cytosol but the significance is smaller (p less than 0.05).
 ...
PMID:Hormonal receptors in endometrial neoplasias. 297 93

Progestogens should be added to estrogen replacement therapy, not only to prevent endometrial cancer in women with a uterus, but also to reduce the risk of breast cancer in some women. Smoking should be discouraged to reduce the risk for both lung cancer and heart disease. Recommendations should be made to increase fiber intake to lessen the risk for carcinoma of the colon. Reducing fat intake also decreases risk for colon cancer, as well as carcinoma of the breast. Postmenopausal bleeding must be investigated for early diagnosis of endometrial cancer and, when endometrial hyperplasia is the finding, it should be treated with progestogens to prevent adenocarcinoma. The progestogen challenge test is recommended for all women with a uterus, and if bleeding occurs, the progestogen should be continued for 13 days each month. Use of mammograms and other diagnostic modalities should be increased to make the earliest possible diagnosis of breast cancer.
 ...
PMID:Cancer in the older woman: diagnosis and prevention. 304 28


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>